First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Summary

A single arm, open label, phase IV trial to evaluate safety and efficacy of icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR.

Timeline

Start

2012-07

Primary completion

2015-12

Completion

2016-04

Drugs

Indications